ID Genomics

Executive Summary

ID Genomics, Inc. is a Seattle-based precision diagnostics company focused on combating antimicrobial resistance through rapid molecular testing. Founded in 2013, the company combines genomic epidemiology with big-data analytics to match infections with the correct antibiotic in real time. Their platform aims to replace traditional culture-based methods, delivering results within hours to guide treatment decisions and reduce the misuse of antibiotics. Operating at the preclinical stage, ID Genomics has not yet commercialized a product but has developed proprietary algorithms and diagnostic panels targeting key pathogens. The company's approach addresses a critical global health challenge, as antibiotic resistance claims over a million lives annually. With no disclosed funding or partnerships, ID Genomics remains a high-risk, high-reward opportunity. Success hinges on clinical validation and securing regulatory clearance for its diagnostic tests. The company operates in a competitive landscape that includes well-funded molecular diagnostics firms, but its niche focus on real-time antibiotic matching could differentiate it if clinical results prove compelling.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Clinical Validation Study for Lead Diagnostic Panel50% success
• Q2 2027Securing Series A or B Funding Round40% success
• Q1 2027Strategic Partnership with Hospital Network for Pilot Deployment35% success